Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:ELUTNASDAQ:PDSBNASDAQ:QTTB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.20-1.2%$1.08$0.86▼$3.60$72.38M0.05285,348 shs51,120 shsELUTElutia$1.87+1.1%$1.91$1.61▼$5.24$76.89M0.8645,136 shs252 shsPDSBPDS Biotechnology$1.44-0.7%$1.45$0.85▼$4.42$65.37M1.27489,909 shs133,255 shsQTTBQ32 Bio$1.60+2.9%$1.71$1.38▼$53.79$19.40M-0.03199,560 shs9,968 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-1.63%-0.82%+18.63%+1.68%-43.98%ELUTElutia+2.21%+3.35%+7.56%-29.92%-47.89%PDSBPDS Biotechnology-3.97%-9.94%+1.40%+15.08%-52.30%QTTBQ32 Bio-0.64%-2.82%-7.74%-9.36%-90.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals1.4842 of 5 stars3.50.00.00.01.41.70.6ELUTElutia3.7 of 5 stars3.55.00.00.02.73.30.6PDSBPDS Biotechnology1.3238 of 5 stars3.71.00.00.02.00.00.0QTTBQ32 Bio2.9016 of 5 stars3.14.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$6.33429.99% UpsideELUTElutia 3.00Buy$8.00327.81% UpsidePDSBPDS Biotechnology 3.33Buy$9.00525.00% UpsideQTTBQ32 Bio 2.25Hold$12.17662.80% UpsideCurrent Analyst Ratings BreakdownLatest QTTB, ELUT, PDSB, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.003/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.003/27/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $13.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/AELUTElutia$24.38M3.15N/AN/A($1.31) per share-1.43PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/AQTTBQ32 Bio$1.16M16.78N/AN/A$0.47 per share3.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)ELUTElutia-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%7/28/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)QTTBQ32 Bio-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)Latest QTTB, ELUT, PDSB, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/A3/27/2025Q4 2024PDSBPDS Biotechnology-$0.29-$0.21+$0.08-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.198.028.02ELUTElutiaN/A0.810.70PDSBPDS Biotechnology0.292.332.33QTTBQ32 Bio1.684.714.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ELUTElutia74.03%PDSBPDS Biotechnology26.84%QTTBQ32 Bio31.32%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%ELUTElutia27.60%PDSBPDS Biotechnology9.20%QTTBQ32 Bio40.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million54.94 millionOptionableELUTElutia18041.12 million29.77 millionNot OptionablePDSBPDS Biotechnology2045.71 million41.51 millionOptionableQTTBQ32 Bio3912.20 million7.32 millionN/AQTTB, ELUT, PDSB, and ABOS HeadlinesRecent News About These CompaniesQ32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical OfficerJune 25 at 6:59 AM | prnewswire.comQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comQ32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia AreataApril 30, 2025 | prnewswire.comLeerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)April 18, 2025 | markets.businessinsider.comQ32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia AreataApril 16, 2025 | prnewswire.comAll You Need to Know About Q32 Bio (QTTB) Rating Upgrade to BuyApril 8, 2025 | zacks.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)March 12, 2025 | markets.businessinsider.comQ32 Bio price target lowered to $15 from $16 at Wells FargoMarch 12, 2025 | markets.businessinsider.comQ32 Bio Reports Promising Trial Results and FinancialsMarch 11, 2025 | tipranks.comQ32 Bio: Q4 Earnings SnapshotMarch 11, 2025 | sfgate.comQ32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate UpdateMarch 11, 2025 | prnewswire.comQ32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibartMarch 10, 2025 | markets.businessinsider.comQ32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology MeetingMarch 8, 2025 | prnewswire.comQ32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual MeetingFebruary 28, 2025 | prnewswire.comQ32 Bio to Participate in Upcoming March Investor ConferencesFebruary 26, 2025 | prnewswire.comPiper Sandler Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comBMO Capital Downgrades Q32 Bio (QTTB)February 12, 2025 | msn.comQ32 Bio (NASDAQ:QTTB) Stock Quotes, Forecast and News SummaryFebruary 12, 2025 | benzinga.comQ32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitorFebruary 11, 2025 | fiercebiotech.comFPiper Sandler cuts Q32 Bio stock rating to neutral, slashes targetFebruary 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTTB, ELUT, PDSB, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.20 -0.02 (-1.24%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Elutia NASDAQ:ELUT$1.87 +0.02 (+1.08%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.PDS Biotechnology NASDAQ:PDSB$1.44 -0.01 (-0.69%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Q32 Bio NASDAQ:QTTB$1.60 +0.05 (+2.90%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Tesla: The Next Month Could Make or Break the Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
